Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 401–500 of 2,162
Brennan, F. R., Cavagnaro, J., McKeever, K., Ryan, P. C., Schutten, M. M., Vahle, J., Weinbauer, G. F., Marrer-Berger, E., & Black, L. E. (2018) · mAbs · doi:10.1080/19420862.2017.1389364 · Cited by 70
Safety of biologics, lessons learnt from TGN1412
Stebbings, R., Poole, S., & Thorpe, R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.002 · Cited by 70
Ansell, S. M., Flinn, I. W., Taylor, M. H., Sikic, B. I., Brody, J., Nemunaitis, J. J., Feldman, A. L., Hawthorne, T. R., Rawls, T., Keler, T., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001079 · Cited by 72
“Patients were also closely monitored for infusion reactions or cytokine release syndrome.(18) Adverse events were coded with the latest available version of the Medical Dictionary for Regulatory Activities and graded according to the National Cancer Institute–issued Common Terminology Criteria for Adverse Events versi…”
MethodWilson, J., & Hunter, D. L. (2010) · The American Journal of Bioethics · doi:10.1080/15265161.2010.482630 · Cited by 84
Dulhunty, J. M., Lipman, J., & Finfer, S. R. (2008) · Intensive Care Medicine · doi:10.1007/s00134-008-1160-2 · Cited by 90
“That multi-organ dysfunction can occur rapidly following cytokine release has been eloquently demonstrated in a case series report of 6 healthy participants who unexpectedly developed SNISIRS following administration of an experimental compound (monoclonal antibody TGN1412) [23].”
BackgroundFidock, M. D., Souberbielle, B. E., Laxton, C. D., Rawal, J. K., Delpuech-Adams, O. E., Corey, T., Colman, P., Kumar, V., Cheng, J. B., Wright, K., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.60 · Cited by 73
Bonamichi-Santos, R., & Castells, M. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8556-5 · Cited by 74
Heslop, H. E. (2010) · Molecular Therapy · doi:10.1038/mt.2010.42 · Cited by 70
A critical appraisal of treatment decisions in multiple sclerosis—old versus new
Kieseier, B. C., & Stüve, O. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.41 · Cited by 70
Tumor immunotherapy: New aspects of natural killer cells
Li, Y., & Sun, R. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.02 · Cited by 76
Toward Better Understanding and Management of CAR-T Cell–Associated Toxicity
Schmidts, A., Wehrli, M., & Maus, M. V. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-061119-015600 · Cited by 72
A coalition to heal—the impact of the cardiac microenvironment
Tzahor, E., & Dimmeler, S. (2022) · Science · doi:10.1126/science.abm4443 · Cited by 68
“caused a cytokine storm (98), which halted further drug development.”
BackgroundRole of immune activation in HIV pathogenesis
Hunt, P. W. (2007) · Current HIV/AIDS Reports · doi:10.1007/s11904-007-0007-8 · Cited by 77
Unexpected Hematologic Effects of Biotherapeutics in Nonclinical Species and in Humans
Everds, N. E., & Tarrant, J. M. (2013) · Toxicologic Pathology · doi:10.1177/0192623312467400 · Cited by 69
“Patients treated with TGN1412 had lymphopenia and monocytopenia at 24 hours postdose (Suntharalingam et al. 2006).”
BackgroundPoirier, N., Blancho, G., Hiance, M., Mary, C., Assche, T. V., Leempoels, J., Ramael, S., Wang, W., Thépenier, V., Braudeau, C., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601538 · Cited by 71
Vessillier, S., Eastwood, D., Fox, B. J., Sathish, J. G., Sethu, S., Dougall, T., Thorpe, S. J., Thorpe, R., & Stebbings, R. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.04.020 · Cited by 76
“…result was achieved in the context of SP presentation and that depletion of RBCs alone would be unlikely to fully restore responses to TGN1412 as it would be similar to the insensitive PBMC CRA which failed to predict the severity of the in vivo outcome (TeGenero, 2005; Stebbings et al., 2007).”
BackgroundMethodImplications of the BIA‐102474‐101 study for review of first‐into‐human clinical trials
Eddleston, M., Cohen, A. F., & Webb, D. J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12920 · Cited by 66
Early Implementation of QbD in Biopharmaceutical Development: A Practical Example
Zurdo, J., Arnell, A., Obrezanova, O., Smith, N., Gómez de la Cuesta, R., Gallagher, T. R. A., Michael, R., Stallwood, Y., Ekblad, C., Abrahmsén, L., et al. (2015) · BioMed Research International · doi:10.1155/2015/605427 · Cited by 66
“any sample contamination or errors in the manufacturing, formulation, dilution or administration of TGN1412 that led to the CRS response [63, 82–86].”
BackgroundStrategies to Modulate Immune Responses: A New Frontier for Gene Therapy
Arruda, V. R., Favaro, P., & Finn, J. D. (2009) · Molecular Therapy · doi:10.1038/mt.2009.150 · Cited by 66
Immunotherapy of Malignant Disease Using Chimeric Antigen Receptor Engrafted T Cells
Maher, J. (2012) · ISRN Oncology · doi:10.5402/2012/278093 · Cited by 72
“In addition to resuscitative measures, treatment may involve the use of high dose corticosteroids and a biological agent [134], although firm evidence in support of any specific choice is lacking.”
BackgroundPolson, A. G., & Fuji, R. N. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01916.x · Cited by 66
“This acute cytokine reaction did not occur in the non-human primate study (Suntharalingam et al., 2006; Stebbings et al., 2007).”
BackgroundA clinical and biological perspective of human myeloid-derived suppressor cells in cancer
Shipp, C., Speigl, L., Janssen, N., Martens, A., & Pawelec, G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2278-y · Cited by 69
Mau‐Sørensen, M., Dittrich, C., Dienstmann, R., Lassen, U., Büchler, W., Martinius, H., & Tabernero, J. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2728-5 · Cited by 70
“In 2006, in a phase I study, all participating healthy volunteers treated with the potent T cell receptor superagonist TGN1412 experienced severe uncontrolled cytokine storms at the initial dose level [21].”
BackgroundA new nucleic acid–based agent inhibits cytotoxic T lymphocyte–mediated immune disorders
Wang, C., Chung, W., Cheng, Y., Ying, N.-W., Peck, K., Chen, Y.-T., & Chung, W. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.036 · Cited by 66
T Cell Cosignaling Molecules in Transplantation
Ford, M. L. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.012 · Cited by 70
Coppola, C. D., Hopkins, B., Huhn, S. C., Du, Z., Huang, Z. J., & Kelly, W. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217814 · Cited by 74
“Scientists have a better understanding of CRS and cytokine storm associated with especially the T cell immunotherapies now that there is a diverse set of data relating to different types of cancers as well as different demographics [32].”
BackgroundInfluentialF lt3 ligand expands CD 4+ F ox P 3+ regulatory T cells in human subjects
Klein, O., Ebert, L. M., Zanker, D. J., Woods, K., Tan, B. S., Fucikova, J. P., Behren, A., Davis, I. D., Maraskovsky, E., Chen, W., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201242603 · Cited by 67
Immunotherapy opportunities in ovarian cancer
Chu, C., Kim, S. H., June, C. H., & Coukos, G. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.2.243 · Cited by 67
Liu, D., Krummey, S. M., Badell, I. R., Wagener, M. E., Schneeweis, L. A., Stetsko, D. K., Suchard, S. J., Nadler, S. G., & Ford, M. L. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20130902 · Cited by 67
“Therapeutic use of anti-CD28 antibody was previously attempted in the TGN1412 study, in which an agonistic anti-CD28 F c -intact monoclonal antibody resulted in massive T cell activation and “cytokine storm” in a Phase I clinical trial (Suntharalingam et al., 2006).”
Harnessing the power of regulatory T‐cells to control autoimmune diabetes: overview and perspective
Yu, H., Paiva, R., & Flavell, R. A. (2017) · Immunology · doi:10.1111/imm.12867 · Cited by 70
Monoclonal Antibody First Dose Cytokine Release Syndromes–Mechanisms and Prediction
Wing, M. G. (2008) · Journal of Immunotoxicology · doi:10.1080/15476910801897433 · Cited by 64
“The severity of this life threatening reaction, which required the volunteers to be admitted to an intensive care unit (Suntharalingam et al., 2006), has sparked a wide ranging international debate on the adequacy of drug development guidelines for biotechnology derived pharmaceuticals and the…”
BackgroundInfluentialLondon, A. J. (2012) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2012.00722.x · Cited by 68
Tvedt, T. H. A., Vo, A. K., Bruserud, Ø., & Reikvam, H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215190 · Cited by 68
“This is illustrated by the phase I clinical trial of the CD28-targeting TGN1412 monoclonal antibody [8], where six healthy volunteers experienced severe CRS requiring intensive care treatment within few hours for participants [8].”
MethodNKT cell costimulation: experimental progress and therapeutic promise
Heuvel, M. J. V. D., Garg, N., Kaer, L. V., & Haeryfar, S. M. M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.007 · Cited by 71
“One classic example was the case of excessive toxicity and a severe systemic inflammatory response experienced by healthy volunteers receiving an agonistic anti-CD28 mAb [91], which had not been observed in animal models.”
BackgroundThe case for induced pluripotent stem cell‐derived cardiomyocytes in pharmacological screening
Khan, J. M., Lyon, A. R., & Harding, S. E. (2013) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02118.x · Cited by 63
“This has been a problem with monoclonal antibodies in other areas, such as the TGN1412 antibody, which produced unexpected cytokine storms in healthy human subjects (Suntharalingam et al., 2006).”
BackgroundInnate Immune Signaling Activated by MDR Bacteria in the Airway
Parker, D., Ahn, D. S., Cohen, T. S., & Prince, A. S. (2015) · Physiological Reviews · doi:10.1152/physrev.00009.2015 · Cited by 76
Newsome, B. W., & Ernstoff, M. S. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03187.x · Cited by 77
Ye, C., Yang, H., Cheng, M., Shultz, L. D., Greiner, D. L., Brehm, M. A., & Keck, J. (2020) · The FASEB Journal · doi:10.1096/fj.202001203r · Cited by 62
Magee, C. N., Boenisch, O., & Najafian, N. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04180.x · Cited by 86
“Use of a superagonistic anti-CD28 mAb in rodent models was shown to preferentially activate and expand functional Tregs both in vitro and in vivo (105,106); unfortunately, attempts to translate this therapy into clinical use were disastrous: in Phase I clinical trials, six healthy volunteers developed a massive cytoki…”
BackgroundLiang, M., Schwickart, M., Schneider, A. K., Vainshtein, I., Nagro, C. J. D., Standifer, N. E., & Roskos, L. K. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21259 · Cited by 66
Human immunity in vitro — Solving immunogenicity and more
Giese, C., & Marx, U. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.011 · Cited by 67
Preclinical models of arthritic disease in non-human primates
Vierboom, M., Jonker, M., Tak, P. P., et al. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.02.012 · Cited by 62
Hypercostimulation through 4-1BB Distorts Homeostasis of Immune Cells
Lee, S., Salek‐Ardakani, S., Mittler, R. S., & Croft, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803241 · Cited by 68
Developability assessment as an early de-risking tool for biopharmaceutical development
Zurdo, J. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.3 · Cited by 75
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction
Ingrasciotta, Y., Cutroneo, P. M., Marcianò, I., Giezen, T. J., Atzeni, F., & Trifirò, G. (2018) · Drug Safety · doi:10.1007/s40264-018-0684-9 · Cited by 71
Targeting B7‐1 in immunotherapy
Chen, R., Ganesan, A., Okoye, I., Arutyunova, E. I., Elahi, S., Lemieux, M. J., & Barakat, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21632 · Cited by 67
The Use of Microfluidic Platforms to Probe the Mechanism of Cancer Cell Extravasation
Coughlin, M. F., & Kamm, R. D. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901410 · Cited by 60
Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs
Chenoweth, A. M., Wines, B. D., Anania, J. C., & Hogarth, P. M. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12326 · Cited by 76
“Unmodified IgG irrespective of its subclass or intended therapeutic effect has the potential to engage an FccR which may lead to suboptimal therapeutic performance or to unexpected and catastrophic consequences.(57,59) Clearly reducing or eliminating FccR interactions, when they are not required for therapeutic effect…”
BackgroundZhang, H., Huanying, Z., Zhu, J., Dong, Q., Wang, J., Fan, H., Chen, Y., Zhang, X., Han, X., Li, Q., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00758 · Cited by 61
New Reagents on the Horizon for Immune Tolerance
St. Clair, E. W., Turka, L. A., Saxon, A., Matthews, J. B., Sayegh, M. H., Eisenbarth, G. S., & Bluestone, J. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145449 · Cited by 62
Räth, T., Billmeier, U., Ferrazzi, F., Vieth, M. W., Ekici, A. B., Neurath, M. F., & Atreya, R. N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01700 · Cited by 71
“Since the induction of cytokine release by therapeutic antibodies is a known side effect that can have deleterious clinical consequences (51), we first analyzed whether VDZ alters or induces the expression of various cytokines.”
BackgroundApplication of new approach methodologies for nonclinical safety assessment of drug candidates
Beilmann, M., Adkins, K., Boonen, H. C. M., Hewitt, P. G., Hu, W., Mader, R., Moore, S., Rana, P., Steger‐Hartmann, T., Villenave, R., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01182-9 · Cited by 85
“119).”
Mariotte, D., Dupont, B., Gervais, R., Galais, M., Laroche, D., Tranchant, A., Comby, E., Bouhier‐Leporrier, K., Reimund, J., & Mauff, B. L. (2011) · mAbs · doi:10.4161/mabs.3.4.16293 · Cited by 62
“The former, consisting of flulike symptoms of varying intensities that are likely due to the interaction of the mAb with the target itself, as has been observed with OKT3, rituximab and more recently with anti-CD28.(1-3) HSR is related to IgE-dependent mechanisms and is usually observed after repeated injections of th…”
BackgroundCharacterization of the human T cell response to in vitro CD27 costimulation with varlilumab
Ramakrishna, V., Sundarapandiyan, K., Zhao, B., Bylesjö, M., Marsh, H. C., & Keler, T. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0080-2 · Cited by 70
Chonan, M., Saito, R., Shoji, T., Shibahara, I., Kanamori, M., Sonoda, Y., Watanabe, M., Kikuchi, T., Ishii, N., & Tominaga, T. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov090 · Cited by 62
Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition
Brzostek, J., Gascoigne, N. R. J., & Rybakin, V. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00024 · Cited by 72
“However, targeting CD28 with the superagonistic monoclonal antibody TGN1412 was a tragic failure, when administration of the antibody during a phase I clinical trial induced severe systemic inflammatory responses in healthy volunteers (3).”
BackgroundB lymphocytes and lupus nephritis: New insights into pathogenesis and targeted therapies
Bhat, P., & Radhakrishnan, J. (2007) · Kidney International · doi:10.1038/sj.ki.5002663 · Cited by 61
The Drug Development Crisis: Efficiency and Safety
Caskey, C. T. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.58.042705.124037 · Cited by 77
“Dramatic adverse outcomes of a FIM clinical study of a CD28 binding protein (a pivotal receptor in immune response) were recently reported (42).”
BackgroundPorciello, N., & Tuosto, L. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.02.004 · Cited by 61
Sullivan, R. J., LoRusso, P. M., & Flaherty, K. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2151 · Cited by 64
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Donnadieu, E., Luu, M., Alb, M., Anliker, B., Arcangeli, S., Bonini, C., Angelis, B. D., Choudhary, R., Espie, D., Galy, A. H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003486 · Cited by 69
In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes
Wyant, T. L., Yang, L., & Fedyk, E. R. (2013) · mAbs · doi:10.4161/mabs.26392 · Cited by 60
Jiménez, S. A., & Piera-Velázquez, S. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.04.004 · Cited by 65
“This event was a Phase 1 clinical trial of TGN1412, a humanized monoclonal anti-CD28 receptor antibody [37].”
BackgroundTherapeutic T-cell manipulation in rheumatoid arthritis: past, present and future
Isaacs, J. D. (2008) · Rheumatology · doi:10.1093/rheumatology/ken163 · Cited by 60
“The life-threatening cytokine storm experienced by the human volunteers was difficult to replicate in vitro even after the event and has resulted in further safeguards during mAb development [ 62 , 63].”
InfluentialThe Model Organism Dictyostelium discoideum
Bozzaro, S. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-302-2_2 · Cited by 68
Biological therapies in rheumatic diseases.
Conti, F., Ceccarelli, F., Massaro, L., Cipriano, E., Franco, M. D., Alessandri, C., Spinelli, F. R., & Scrivo, R. (2013) · PubMed · doi:10.7417/ct.2013.1622 · Cited by 75
“Unfortunately, the administration of an antibody against CD28 in healthy volunteers evoked a cytokine storm associated with multiorgan failure (104).”
BackgroundThe past, present, and future of costimulation blockade in organ transplantation
Schroder, P. M., Fitch, Z. W., Schmitz, R., Choi, A. Y., Kwun, J., & Knechtle, S. J. (2019) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000656 · Cited by 60
“Briefly, this strategy suffered a setback when a phase I clinical trial using a CD28-specific mAb known as theralizumab (TGN1412) reported life-threatening cyotokine release syndrome and nonspecific T cell activation requiring admission to the intensive care unit in all six healthy trial participants [65].”
BackgroundImmunotherapy for neurological diseases
Villoslada, P., Moreno, B., Melero, I., Pablos, J. L., Martino, G., Uccelli, A., Montalbán, X., Ávila, J., Rivest, S., Acarín, L., et al. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.04.003 · Cited by 71
“However, unwanted side effects, such as the induction of vitiligo in patients treated with an anti-CTLA4 antibody indicate that manipulation of the immune system must be carefully controlled [3].”
BackgroundVille, S., Poirier, N., Blancho, G., & Vanhove, B. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00411 · Cited by 66
The many faces of FcγRI: implications for therapeutic antibody function
Swisher, J. F. A., & Feldman, G. M. (2015) · Immunological Reviews · doi:10.1111/imr.12334 · Cited by 70
“It is interesting to note that the most infamous therapeutic antibody in this regard—TGN1412, which induced multi-organ failure in the six healthy volunteers who received a single dose (133)—was an IgG4 as well.”
BackgroundOstrowski, S. R., Katzenstein, T. L., Pedersen, B. K., Gerstoft, J., & Ullum, H. (2008) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2008.02184.x · Cited by 67
Assessing the Safety of Adjuvanted Vaccines
Ahmed, S., Plotkin, S. A., BLACK, S. B., & Coffman, R. L. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002302 · Cited by 61
Experimental animal modeling for immuno-oncology
Li, Q., Feuer, G., Ouyang, X., & An, X. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.002 · Cited by 67
PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS: NEW STRATEGY, NEW TARGETS
Nasonov, E. L. (2017) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2017-409-419 · Cited by 69
Brooks, K. M., George, J. M., Pau, A. K., Rupert, A. W., Mehaffy, C., De, P., Dobos, K. M., Kellogg, A., McLaughlin, M. E., McManus, M., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy082 · Cited by 59
Adaptive Immune Responses Contribute to Post-ischemic Cardiac Remodeling
Santos‐Zas, I., Lemarie, J., Tedgui, A., & Ait‐Oufella, H. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00198 · Cited by 67
Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies
Lynch, C. M., Hart, B. W., & Grewal, I. S. (2009) · mAbs · doi:10.4161/mabs.1.1.7377 · Cited by 59
Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release
Eastwood, D., Bird, C., Dilger, P., Hockley, J., Findlay, L., Poole, S., Thorpe, S. J., Wadhwa, M., Thorpe, R., & Stebbings, R. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12165 · Cited by 58
Inhibitory receptor agonists: the future of autoimmune disease therapeutics?
Grebinoski, S., & Vignali, D. A. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.06.001 · Cited by 58
“Current Opinion in Immunology 2020, 67:1–9 (4) What is the best way to target IRs in an agonistic manner? (Figure 1, Tables 1–3) Agonist antibodies can be challenging to generate, but potent examples exist, such as the CD28 agonist TGN1412, which caused detrimental cytokine storms in phase 1 trials [47].”
BackgroundConsensus on the Key Characteristics of Immunotoxic Agents as a Basis for Hazard Identification
Germolec, D. R., Lebrec, H. N., Anderson, S. E., Burleson, G. R., Cárdenas, A., Corsini, E., Elmore, S. E., Kaplan, B. L. F., Lawrence, B. P., Lehmann, G. M., et al. (2022) · Environmental Health Perspectives · doi:10.1289/ehp10800 · Cited by 65
Tada, M., Ishii‐Watabe, A., Suzuki, T., & Kawasaki, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095787 · Cited by 62
“[40,41] There are some putative molecular mechanisms in which mAbs cause the release of inflammatory cytokines. mAbs targeting the cell-surface antigens expressed in immune cells may induce the cytokine release from the target cells by agonistic activity (e.g., muromonab-CD3 [42] and TGN1412 [43]).”
BackgroundTherapeutic Monoclonal Antibodies
Yamada, T. (2011) · The Keio Journal of Medicine · doi:10.2302/kjm.60.37 · Cited by 78
Fan, Z., Zhao, G., Li, J., Osada, N., Xing, J., Yi, Y., Du, L., Silva, P., Wang, H., Sakate, R., et al. (2014) · Molecular Biology and Evolution · doi:10.1093/molbev/msu104 · Cited by 62
“Despite the high conservation of the primate immune system, clinical trials have shown that responses in macaques are not good predictors of human defense reactions, likely due to mutations in immune-related genes (Suntharalingam et al. 2006).”
BackgroundStatistical Issues in First-In-Man Studies
Senn, S. J., Amin, D. M., Bailey, R. A., Bird, S. M., Bogacka, B., Colman, P., Garrett, A., Grieve, A. P., & Lachmann, P. J. (2007) · Journal of the Royal Statistical Society Series A (Statistics in Society) · doi:10.1111/j.1467-985x.2007.00481.x · Cited by 57
“A European drug regulatory authorities’ harmonized application is accompanied on the Web site of the Medicines Control Agency Clinical Trials Unit (now the MHRA) by annex 5 which gives illustrative guidance in mock applications for two fictitious products: (a) chemical compound AB1234—a proton pump inhibitor being dev…”
BackgroundInfluentialMeersseman, P., Langouche, L., du Plessis, J., Korf, H., Mekeirele, M., Laleman, W., Nevens, F., Wilmer, A. P., den Berghe, G. V., & der Merwe, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.025 · Cited by 59
CD28 Superagonists: What Makes the Difference in Humans?
Schraven, B. L., & Kalinke, U. (2008) · Immunity · doi:10.1016/j.immuni.2008.04.003 · Cited by 63
Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies
Hünig, T. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)95004-x · Cited by 57
Microtools for single-cell analysis in biopharmaceutical development and manufacturing
Love, K. R., Bagh, S., Choi, J. H., & Love, J. C. (2013) · Trends in biotechnology · doi:10.1016/j.tibtech.2013.03.001 · Cited by 56
Bispecific Antibodies for Triple Negative Breast Cancer
Dees, S., Ganesan, R., Singh, S., & Grewal, I. S. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.09.004 · Cited by 61
Giezen, T. J., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., et al. (2009) · Drug Safety · doi:10.2165/11318980-000000000-00000 · Cited by 57
Coch, C., Lück, C., Schwickart, A., Putschli, B., Renn, M., Höller, T., Barchet, W., Hartmann, G., & Schlee, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071057 · Cited by 57
“Due to the Tegenero desaster [13] it became aware that the life-threatening side effects of excessive cytokine release by an immune activating drug is difficult to predict since the immune system is highly species specific.”
BackgroundLevin, S. E., Zhang, C., Kadlecek, T. A., Shokat, K. M., & Weiss, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709000200 · Cited by 57
Living in LALA land? Forty years of attenuating Fc effector functions
Hale, G. (2024) · Immunological Reviews · doi:10.1111/imr.13379 · Cited by 63
Pharmacogenomics in Early-Phase Clinical Development
Burt, T., & Dhillon, S. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.81 · Cited by 57
Antiviral applications of Toll-like receptor agonists
Horscroft, N., Pryde, D. C., & Bright, H. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr588 · Cited by 61
Soto, P. C., Stein, L. L., Hurtado-Ziola, N., Hedrick, S. M., & Varki, A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903420 · Cited by 56
Generation and preclinical characterization of an antibody specific for SEMA4D
Fisher, T. L., Reilly, C. A., Winter, L. A., Pandina, T., Jonason, A., Scrivens, M., Balch, L., Bussler, H., Torno, S., Seils, J., et al. (2016) · mAbs · doi:10.1080/19420862.2015.1102813 · Cited by 55
From germ-free to wild: modulating microbiome complexity to understand mucosal immunology
Thomson, C. A., Morgan, S., Ohland, C., & McCoy, K. D. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00562-3 · Cited by 62
“) However, the CD28-superantigen human clinical trial resulted in overt over-activation of inflammatory T cells followed by cytokine storm and a lack of Treg expansion.(129) These catastrophic effects were recapitulated wildlings but not SPF mice.”
BackgroundUpregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412
Hussain, K., Hargreaves, C. E., Roghanian, A., Oldham, R. J., Chan, H. T. C., Mockridge, C. I., Chowdhury, F., Frendéus, B., Harper, K., Strefford, J. C., et al. (2014) · Blood · doi:10.1182/blood-2014-08-593061 · Cited by 63
“However, anti-CD28 mAbs suffered a major setback when the first-in-man trial of TGN1412 caused life-threatening CRS.(1) TGN1412, a so-called “superagonist,” is able to stimulate T-cell activation without TCR engagement.”
BackgroundInfluentialA Monovalent Anti-Human CD28 Domain Antibody Antagonist: Preclinical Efficacy and Safety
Suchard, S. J., Davis, P. M., Kansal, S., Stetsko, D. K., Brosius, R., Tamura, J. K., Schneeweis, L. A., Bryson, J. W., Salcedo, T. W., Wang, H., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300470 · Cited by 58
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.